14 posts to 11am
Spread 20% fell back to 0.83p 2/4/24
Back to 1.1p today just two days on .
Bid 1p Ask 1.2p
Another placing today at 1.5 euro = 129p
16% spread showing 130p Bid 120 Ask 140p
itsallamess was lucky not to have funds to top up as I did in July 2022 after the 214p placing , spread 15% then.
Did have a chance to get out in profit December 2022 when they pulled back to 360p
Article on the young man wanting the board removed.
https://teaxall.org/millennial-retail-shareholder-tariq-hamoodis-insights/
Shares in Issue 45.59m
Market Cap. £2.30b
Market Size 750
PE Ratio 4.571157
Earnings 1,104.75321
Dividend 123.39306
Yield 2.443%
Shares in Issue 42.67m
Market Cap. £561.59m
Market Size 1,000
PE Ratio 2.395543
Earnings 549.3536
Dividend 0.00
Yield 0.00%
Sold Another half tranche for $41.75 , saw 7.6% one day rise ( 7.75% at close )
Had a note of being back to original holding before today's sale.
I first bought BGEO 18/5/2018 , shortly after on 29/5/2018 it demerged.
And I had equal amount of BGEO and CGEO .
On 1/7/2019 I buy BGEO a second time acc shows , selling that second buy and out completely of BGEO on 20/11/23.
So I still have original CGEO ( From demerge split )
Then I buy GHG ( Georgia Health ) about 5 months after the second BGEO buy on 20/12/19 ( first buy ) then same amount again 30/12/2019 , and smaller amount on 8/1/2020 third buy ( maybe a rights ? )
On 4/10/2022 GHG are exchanged for CGEO shares but not on a one for one ratio.
like BGEO appear to have gone up 33% this calendar year to all time high .
Higher interest rates and other things boasting the Georgia economy apparently.
I reread this from poster SD235 on the thread I started on BGEO.
RE: Might be of interest to some here .7 Oct 2022 14:34
As I read it Georgia health was demerged from bank of Georgia before Georgia capital. When Georgia capital was demerged it held 66% of the shares of Georgia health. Georgia health did badly on the UK stock exchange so was bought back. I think we can only sell companies to other companies as there is no demand for Georgian companies on theUK stockmarket. Even bank Georgia trades on a p/e of 5 and Georgia capital is on at least a 60% discount.
I think the only way to increse share price of Georgia capital is to pay a dividend but buy backs on a 60% discount have to come first.
5000p now 34% better then the 3750p sell on 20th December 2023.
Georgia Capital also on all year high today .
Tender offer for 24p.
Lombard Odier Asset Management increased on 1/11/23 to 16%
Analysts had expect the price to increase by 187% to 60p ( D )
End of October 2023 hit a low of 15.6p
I see I bought two more times after 11/1/23
17/1/23 for 34p then 20/2/23 for 24p
When I looked for this reminder post 11th January 2023.
Page no longer exists message kept coming up.
Copied
Made a mistake adjusted my buy order at 4.25pm and bought for 40.9p ( on order increased to 41p)
That will teach me to return , instead of heading out .
Mistakes like this worked out ok in the past .
Good job spare funds waiting for a home .
Of course another buy lifted after 10mins on market close auction extra 5min , nearly using the remaining funds .
718 Shares bought today .
700 last time 13/3/24 ( order had been 718 )
A further -15% down today will not be allowed to stay in ISA , if you do not sell.
AIM shares just not worth risking money on .
Wednesday 27th Mar 2024
This from before the Easter break ,
C4X Discovery seeks AIM delisting but half-year revenue skyrockets
(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.
C4X shares dropped 24% to 10.00 pence on late on Wednesday morning in London.
The Manchester, England-based drug discovery company will seek shareholder approval to delist from AIM at a general meeting on April 5. It expects the cancellation to take effect on the morning of April 26.
Following the delisting, C4X intends to re-register as a private limited company.
Chief Executive Officer Clive Dix said the decision follows "an extensive review and deliberation to ascertain the most effective way to maximise shareholder value in the longer term and increase the potential for [our] long-term success".
He added that "the recent downturn in the financial markets has adversely impacted our share price, and with it, our future ability to raise funds in the public markets...we can potentially access a larger quantum of future funding required to accelerate our strategy as a private company".
Also on Wednesday, C4X released its results for the six months to January 31.
The company swung to a GBP17.8 million pretax profit, following its GBP5.2 million loss in the first half of financial 2023.
Revenue, meanwhile, soared to GBP24.6 million from GBP1.7 million.
C4X said this reflected receipt of GBP15.9 million from selling the rights to its Orexin-1 receptor antagonist to Indivior PLC in August, and a USD11 million or GBP8.7 million milestone payment from AstraZeneca PLC. The latter, received in early January, stemmed from preclinical progress of C4X's NRF2 Activator programme which it licensed out to AstraZeneca in November.
Research & Development expenses remained stable at GBP5.2 million, "reflecting focused investment in key drug discovery programmes focused on immune-inflammatory diseases."
Looking ahead, C4X believes it is "in a strong financial position with the potential for further milestone payments over the next 18 months".
It said that once it officially becomes a private company, it will be able to "accelerate our strategy and...maximise revenue from our portfolio", assuming it can access those larger pools of potential funding.
All time low of $1
Bought more today at $1 x 518. ( must be equal to $0.1 pre Consolidation )
Fx 1.2542
Appears 9th August 2023 I could not buy for $4
7th August 23 was the Consolidation 1for10 **
The sell below on 5th August 2022 for $2.41 x 524 , must be equal to $24.1 x 52 shares.
Last week Viavi hoped regulators would block rival higher offer.
RNS from them today.
In a statement, Viavi said its deal represented "certain value" and noted its limited business overlap with Spirent relative to Keysight.
"Viavi believes that the proposed combination of Keysight and Spirent would further entrench Keysight's leading position in many product segments, which would limit customer choice," Viavi said.
RNS today up 23% spread 6.5% to 0.32p.
Lots of chat here.
End of November 2023 post placing low at 0.23p stayed there until mid February , before a spike to 0.35p 21st 2024 February
No harm not buying the placings on AIM.
With the two sales 8/5/17 & 7/6/17 reducing the loss a little , looks like I lost £5,325 here.
Unfortunately made four top ups after the two sales last buy on 25/10/17 for 55p others 158p to 90p.
Then after not taking rights up April 2018 .
Topped up again on 23/10/18 for 7.5p
An example of throwing good money after bad .
No noteS on Barc .
This the last RNS.
6 January 2020
Defenx PLC
("Defenx", the "Company" or the "Group")
Delisting from AIM
Result of Exit Opportunity
Further to the Company's announcement of 4 December 2019, and subsequent approval by Shareholders of the Cancellation at the General Meeting on 20 December 2019, the Company confirms that admission to trading on AIM of the Company's Ordinary Shares will be cancelled at 7.00 a.m. tomorrow, 7 January 2020.
Result of Exit Opportunity
The Company has also been informed by BV Tech that, further to BV Tech's announcement of 4 December 2019 regarding the Exit Opportunity, which closed at 1.00 p.m. today, BV Tech has purchased, in aggregate, 8,070,059 Ordinary Shares pursuant to the Exit Opportunity and is now interested in a total of 34,034,909 Ordinary Shares, representing approximately 87.9 per cent. of the existing issued Ordinary Shares and voting rights in the Company.
Further details of the Cancellation are set out in the Circular posted to shareholders and available on the Company's website at https://investors.defenx.com.